Gain Therapeutics Inc., a clinical-stage biotechnology company, has announced its intention to conduct a public offering of its common stock and warrants to purchase common stock. The company plans to use the net proceeds from this offering to further the clinical and nonclinical development of its lead product candidate, GT-02287, which targets neurodegenerative diseases such as GBA1 Parkinson's disease. Newbridge Securities Corporation is serving as the sole book-running manager for this proposed offering. The offering will be made through a prospectus, and the final terms will depend on the prevailing market conditions at the time of pricing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.